-1.34%
31.09%
53.65%
38.61%
4.90%
264.44%
4.29%
AI Spotlight on BBIO
Company Description
BridgeBio Pharma, Inc.engages in the discovery, development, and delivery of various medicines for genetic diseases.The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones.In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases.
BridgeBio Pharma, Inc.has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc.The company was founded in 2015 and is headquartered in Palo Alto, California.
Market Data
| Last Price | 35.97 |
| Change Percentage | -1.34% |
| Open | 36.42 |
| Previous Close | 36.46 |
| Market Cap ( Millions) | 6798 |
| Volume | 1869688 |
| Year High | 41.04 |
| Year Low | 21.62 |
| M A 50 | 29.02 |
| M A 200 | 27.0 |
Financial Ratios
| FCF Yield | -6.71% |
| Dividend Yield | 0.00% |
| ROE | 37.14% |
| Debt / Equity | -140.64% |
| Net Debt / EBIDTA | -417.82% |
| Price To Book | -5.51 |
| Price Earnings Ratio | -15.45 |
| Price To FCF | -14.9 |
| Price To sales | 31.22 |
| EV / EBITDA | -23.59 |
News
- Jan -15 - BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
- Jan -14 - BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
- Jan -14 - Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?
- Jan -13 - BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
- Jan -13 - BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
- Jan -08 - BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
- Dec -13 - Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Dec -03 - Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
- Nov -26 - BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
- Nov -25 - FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
- Nov -24 - BridgeBio: Next Chapter Begins After Attruby Approval
- Nov -23 - US FDA approves BridgeBio's drug for rare heart condition
- Nov -23 - Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Nov -19 - BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
- Nov -18 - Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
- Nov -18 - BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
- Nov -14 - BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats
- Nov -12 - BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates
- Nov -05 - BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management
- Oct -31 - BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Transformative Medicines
Expected Growth : 10.43 %
What the company do ?
Transformative Medicines from BridgeBio Pharma, Inc. is a subsidiary focused on developing novel therapies for genetically driven diseases.
Why we expect these perspectives ?
Transformative Medicines from BridgeBio Pharma, Inc. is driven by its innovative gene therapy pipeline, strong partnerships, and increasing demand for rare disease treatments. The company's focus on genetic diseases with high unmet needs, such as achondroplasia and Canavan disease, positions it for continued growth.
Bridgebio Pharma, Inc. Products
| Product Range | What is it ? |
|---|---|
| BBP-831 | BBP-831 is a small molecule inhibitor of the A2a receptor, a key regulator of inflammation and immune response. It is being developed as a potential treatment for various inflammatory diseases. |
| ENC-001 | ENC-001 is a gene therapy designed to treat congenital erythropoietic porphyria (CEP), a rare and debilitating genetic disorder. |
| BBP-815 | BBP-815 is a small molecule inhibitor of the PI3K delta enzyme, a key regulator of immune cell function. It is being developed as a potential treatment for various autoimmune diseases. |
| BBP-924 | BBP-924 is a small molecule inhibitor of the SHP2 enzyme, a key regulator of cell signaling pathways. It is being developed as a potential treatment for various cancers. |
| BBP-398 | BBP-398 is a gene therapy designed to treat Canavan disease, a rare and debilitating genetic disorder. |
BridgeBio Pharma, Inc.'s Porter Forces
Threat Of Substitutes
BridgeBio Pharma, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Bargaining Power Of Customers
BridgeBio Pharma, Inc. has a low bargaining power of customers due to the lack of concentration in the buyer's market and the high switching costs.
Bargaining Power Of Suppliers
BridgeBio Pharma, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers and the moderate switching costs.
Threat Of New Entrants
BridgeBio Pharma, Inc. has a high threat of new entrants due to the low barriers to entry and the high growth potential in the biotech industry.
Intensity Of Rivalry
BridgeBio Pharma, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 451.23% |
| Debt Cost | 4.21% |
| Equity Weight | -351.23% |
| Equity Cost | 9.33% |
| WACC | -13.76% |
| Leverage | -128.47% |
BridgeBio Pharma, Inc. : Quality Control
BridgeBio Pharma, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDYA | IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product … |
| TECH | Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, … |
| INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
| ALNY | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, … |
| KRYS | Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bio-Techne
A-Score
1-Year Total Return ->
🥈
Insmed
A-Score
1-Year Total Return ->
🥉
Alnylam Pharmaceuticals
A-Score
1-Year Total Return ->
4
Krystal Biotech
A-Score
1-Year Total Return ->
5
BridgeBio Pharma
A-Score
1-Year Total Return ->
6
